Search Results

Your search for Steven M. Horwitz, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2021 Pan Pacific Lymphoma Conference

Steven M. Horwitz, MD, on Advanced-Stage Mycosis Fungoides and Sezary Syndrome: Update on Management Practices

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses treatments for advanced mycosis fungoides and Sezary syndrome, including brentuximab vedotin and mogamulizumab, and how best to choose among treatments.

lymphoma

immunotherapy

By Matthew Stenger / 2018 ASH Annual Meeting & Exposition / Thursday, December 13, 2018 3:41 PM

ECHELON-2: Brentuximab Vedotin Plus Chemotherapy in CD30-Positive Peripheral T-Cell Lymphoma

As reported by Horwitz et al in The Lancet, the phase III ECHELON-2 trial showed that brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (CHP) improved progression-free and overall survival vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in...

Apr

Today In Oncology

Search Results

Your search for Steven M. Horwitz, MD matches 2 pages

Steven M. Horwitz, MD, on Advanced-Stage Mycosis Fungoides and Sezary Syndrome: Update on Management Practices

ECHELON-2: Brentuximab Vedotin Plus Chemotherapy in CD30-Positive Peripheral T-Cell Lymphoma

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities